Evaluation of Coronavirus Disease 2019-Related Morbidity and Mortality in Lipodystrophy Patients During the Pandemic Period

Basit Öğe Kaydı
dc.contributor.authorSemiz, Gokcen Gungor
dc.contributor.authorDemir, Tevfik
dc.contributor.authorSimsir, Ilgin Yildirim
dc.contributor.authorSelimoglu, Ismail
dc.contributor.authorYilmaz, Muege
dc.contributor.authorEllidokuz, Huelya
dc.contributor.authorOnay, Hueseyin
dc.date.accessioned2024-08-04T20:56:13Z
dc.date.available2024-08-04T20:56:13Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: Coronavirus Disease 2019's (COVID-19) impact on rare disease populations such as lipodystrophy syndromes is unknown. We assessed COVID-19 infection outcomes in lipodystrophy syndromes and aimed to investigate the effect of restricted access to the hospital during the pandemic on metabolic parameters. Methods: A survey form consisting of descriptive questions about the situation of the patients during the COVID-19 pandemic was created. The survey was performed by phone in February and March 2021; all patients gave verbal consent. Patients diagnosed with lipodystrophy syndromes participated in our study. Demographic parameters were recorded. They were asked if they were diagnosed with COVID-19; if so, the hospitalization, intensive care unit need, oxygen requirement, and COVID-19 treatment were questioned. Laboratory data were recorded from the hospital records. Results: Seventy-one patients were investigated. Lipodystrophy patients in our study had at least 1 comorbid disease. Diabetes mellitus was the most common (87.1%). Six patients stated they had a COVID-19 infection (6/71, 8.5%). Three cases (50.0%) were hospitalized, and 1 (16.6%) patient was followed up in the intensive care unit. There were no deaths in our cohort. When the laboratory parameters of the entire group were evaluated, spot urine microalbumin increased significantly compared to the prepandemic period (P P = .013). Conclusion: Lipodystrophy patients may experience COVID-19 more severely due to their numerous comorbidities. Further research should be conducted with larger patient cohorts to investigate this relationship.en_US
dc.description.sponsorshipSociety of Endocrinology and Metabolism of Turkiyeen_US
dc.description.sponsorshipPreparation for publication of this article is supported by the Society of Endocrinology and Metabolism of Turkiye.en_US
dc.identifier.doi10.5152/erp.2024.23352
dc.identifier.endpage155en_US
dc.identifier.issn2822-6135
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85199193276en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage151en_US
dc.identifier.urihttps://doi.org/10.5152/erp.2024.23352
dc.identifier.urihttps://hdl.handle.net/11616/102130
dc.identifier.volume28en_US
dc.identifier.wosWOS:001267516900004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofEndocrinology Research and Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOVID-19en_US
dc.subjectlipodystrophyen_US
dc.subjectmortalityen_US
dc.titleEvaluation of Coronavirus Disease 2019-Related Morbidity and Mortality in Lipodystrophy Patients During the Pandemic Perioden_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu